STOCK TITAN

Pacira BioSciences, Inc. - PCRX STOCK NEWS

Welcome to our dedicated page for Pacira BioSciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences stock.

Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.

Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.

The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.

Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.

Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.

For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net product sales for EXPAREL and iovera° for January 2022. EXPAREL's net sales reached $36.3 million, a 4% increase from January 2021, with average daily sales at 104% of the previous year. Iovera° sales remained steady at $1.1 million. CEO Dave Stack reported growth trends for EXPAREL and the ongoing launch of the next-generation iovera° device. However, the company did not provide 2022 financial guidance due to ongoing uncertainty surrounding COVID-19's impact on elective surgeries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported record net product sales of $506.5 million for 2021, marking a 25.8% increase from 2020. Fourth quarter sales of EXPAREL reached $139.9 million, driven by strong growth, although affected by COVID-19-related restrictions in December. The company also recognized sales of ZILRETTA and iovera°, contributing to total revenue of $540.7 million to $541.7 million for the year. Despite challenges posed by the pandemic, Pacira remains optimistic about future growth in non-opioid pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 PM ET. Interested parties can access the live audio via the company's website, with a replay available for two weeks post-event. Pacira is dedicated to providing non-opioid pain management solutions and has three commercial-stage products: EXPAREL®, ZILRETTA®, and ioveraº®. Their mission focuses on reducing reliance on opioids and developing innovative treatments for chronic pain and related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) has successfully closed a $375 million Senior Secured Term Loan B Facility, enhancing its operational and financial flexibility. The proceeds will be utilized for general corporate purposes, including replenishing funds from the recent acquisition of Flexion Therapeutics and repaying existing convertible senior notes. CFO Charles Reinhart emphasizes confidence in the company's forecasted earnings and operating cash flow, supporting their five-year growth plan aimed at revenue and earnings expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales for November 2021, reporting EXPAREL sales of $46.5 million, a 22% increase from $38.1 million in November 2020. Average daily sales for EXPAREL reached 122% of the previous year. Iovera° reported $1.5 million in sales, up from $0.8 million. The company expects ZILRETTA sales to improve in 2022 following the acquisition of Flexion Therapeutics. Despite these growth trends, uncertainties related to the COVID-19 pandemic and the elective surgery market persist, leading to no financial guidance for 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, at 9:30 AM ET. Investors can access the live audio on the company's website under the 'Events' section. A replay will be available for two weeks after the event. Pacira focuses on providing non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at managing pain and reducing opioid reliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences
Rhea-AI Summary

Pacira BioSciences has completed its acquisition of Flexion Therapeutics, enhancing its offerings in non-opioid pain management. This strategic move incorporates ZILRETTA, a patented treatment for osteoarthritis knee pain, into Pacira's portfolio, allowing earlier intervention for patients. The acquisition is expected to diversify revenue streams and enhance cash flows substantially. CEO David Stack emphasized the significance of this deal in evolving pain management and reducing opioid reliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 11:20 AM GMT. Live audio of the event can be accessed through the company’s website, with a replay available for two weeks after. Pacira is a leader in non-opioid pain management solutions, highlighted by its long-acting local analgesic, EXPAREL, launched in April 2012. The company aims to reduce opioid reliance through innovative therapies and technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for October 2021, noting that EXPAREL achieved sales of $42.5 million, a 4.4% increase from $40.7 million in October 2020. Average daily sales for EXPAREL rose to 109% compared to last year. Sales of iovera° were $1.2 million, up from $1.0 million in the same period. CEO Dave Stack expressed confidence in strong growth ahead, citing improved market conditions for elective surgeries. The company also plans to integrate ZILRETTA post-acquisition of Flexion Therapeutics, aiming for annual growth in the high teens and over 50% operating margins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) has filed a lawsuit against eVenus Pharmaceutical Laboratories for patent infringement related to EXPAREL (bupivacaine liposome injectable suspension), protecting U.S. Patent Number 11,033,495, which expires on January 22, 2041. The lawsuit triggers a 30-month stay on eVenus’ ANDA approval under the Hatch Waxman Act. This marks a significant step in Pacira's patent strategy, as the company aims to defend its intellectual property against potential generic competition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none

FAQ

What is the current stock price of Pacira BioSciences (PCRX)?

The current stock price of Pacira BioSciences (PCRX) is $23.34 as of January 23, 2025.

What is the market cap of Pacira BioSciences (PCRX)?

The market cap of Pacira BioSciences (PCRX) is approximately 1.0B.

What is Pacira BioSciences, Inc. known for?

Pacira BioSciences is recognized for its innovative non-opioid pain management solutions and regenerative health treatments, including products like EXPAREL, ZILRETTA, and ioveraº.

What are Pacira BioSciences' main products?

The main products include EXPAREL, a long-acting local analgesic, ZILRETTA, an extended-release injection for osteoarthritis knee pain, and ioveraº, a device for drug-free pain control.

What is EXPAREL used for?

EXPAREL is used for postsurgical pain management, providing long-lasting pain relief and significantly reducing the need for opioids.

What recent financial milestone did Pacira achieve?

Pacira reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023.

What is ZILRETTA?

ZILRETTA is an extended-release, intra-articular corticosteroid injection indicated for managing osteoarthritis knee pain.

How does ioveraº work?

ioveraº delivers precise, controlled doses of cold temperature to targeted nerves for immediate, long-lasting, drug-free pain relief.

What is the DepoFoam® delivery platform?

DepoFoam® is a proprietary product delivery technology by Pacira that encapsulates drugs in multivesicular liposomes, releasing them over a desired period without altering their molecular structure.

What are Pacira’s plans for 2024?

Pacira plans to launch EXPAREL in two key lower extremity nerve blocks and prepare for the NOPAIN Act rollout in 2025 to expand patient access to opioid-sparing pain management.

What is PCRX-201?

PCRX-201 is a gene therapy product candidate for osteoarthritis, recently granted FDA RMAT designation and European Medicines Agency ATMP designation.

Where can I learn more about Pacira BioSciences?

For more information, visit Pacira BioSciences’ official website at www.pacira.com.
Pacira BioSciences, Inc.

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.04B
45.13M
2.15%
114.51%
10.29%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TAMPA